Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Stock Has Average Target Price of $13.08 According to Analysts

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) have received a consensus rating of “Hold” from the nine research firms that are covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and six have given a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $13.08.

VNDA has been the topic of a number of recent research reports. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Vanda Pharmaceuticals in a report on Monday. Zacks Research lowered Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday. Oppenheimer assumed coverage on Vanda Pharmaceuticals in a report on Wednesday, September 23rd. They set an “outperform” rating and a $10.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Friday, July 17th. Finally, B. Riley Financial reissued a “buy” rating and issued a $12.00 price target (down from $17.00) on shares of Vanda Pharmaceuticals in a research note on Monday, August 10th.

Institutional Trading of Vanda Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. State Street Corp boosted its stake in shares of Vanda Pharmaceuticals by 16.6% in the 2nd quarter. State Street Corp now owns 3,516,405 shares of the biopharmaceutical company’s stock valued at $21,520,000 after purchasing an additional 500,843 shares during the last quarter. Syon Capital LLC bought a new position in Vanda Pharmaceuticals during the second quarter worth $125,000. Hsbc Holdings PLC raised its stake in Vanda Pharmaceuticals by 144.5% during the second quarter. Hsbc Holdings PLC now owns 94,988 shares of the biopharmaceutical company’s stock worth $579,000 after buying an additional 56,133 shares during the last quarter. Wellington Management Group LLP acquired a new position in Vanda Pharmaceuticals in the second quarter valued at $220,000. Finally, Jefferies Financial Group Inc. bought a new stake in Vanda Pharmaceuticals during the second quarter valued at $749,000. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals Stock Performance

NASDAQ:VNDA opened at $4.53 on Friday. The stock’s 50-day moving average is $5.14 and its 200-day moving average is $5.92. Vanda Pharmaceuticals has a 1-year low of $4.27 and a 1-year high of $9.94. The company has a current ratio of 1.61, a quick ratio of 1.60 and a debt-to-equity ratio of 0.01. The stock has a market cap of $273.88 million, a P/E ratio of -0.98 and a beta of 0.69.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.46). Vanda Pharmaceuticals had a negative return on equity of 49.81% and a negative net margin of 127.41%.The business had revenue of $50.53 million for the quarter, compared to analyst estimates of $61.92 million. Equities research analysts anticipate that Vanda Pharmaceuticals will post -3.02 earnings per share for the current year.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company was founded in 2003 and is headquartered in Washington, DC Its work centers on conditions involving sleep, circadian rhythms, and psychiatric health.

Vanda’s commercial products include Hetlioz (tasimelteon), a melatonin receptor agonist approved in the United States for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis Syndrome, and Fanapt (iloperidone), an atypical antipsychotic used to treat schizophrenia in adults.